ChemoCentryx traded at $26.76 this Friday July 1st, increasing $1.98 or 7.99 percent since the previous trading session. Looking back, over the last four weeks, ChemoCentryx gained 15.94 percent. Over the last 12 months, its price rose by 103.03 percent. Looking ahead, we forecast ChemoCentryx to be priced at 25.45 by the end of this quarter and at 23.45 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
26.76
Daily Change
7.99%
Yearly
103.03%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,759.00 -59.00 -1.55% 0.16%
AbbVie 153.80 0.64 0.42% 33.54%
Alnylam Pharmaceuticals 148.25 2.40 1.65% -13.52%
Amgen 245.55 2.25 0.92% -1.27%
AstraZeneca 10,754.00 -46.00 -0.43% 22.50%
Bayer 57.35 0.63 1.11% 11.42%
Biogen 210.63 6.69 3.28% -39.60%
BioMarin Pharmaceutical 84.98 2.11 2.55% -0.57%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
ChemoCentryx 26.76 1.98 7.99% 103.03%
GlaxoSmithKline 1,785.60 20.00 1.13% 24.19%
Glaxosmithkline 43.75 0.22 0.51% 8.27%
Incyte Corp 77.67 1.70 2.24% -7.07%
J&J 179.52 2.01 1.13% 6.24%
MacroGenics 3.05 0.10 3.39% -89.37%
Merck & Co 92.42 1.25 1.37% 17.58%
Mirati Therapeutics 71.18 4.05 6.03% -57.53%
Novartis 80.33 -0.52 -0.64% -4.96%
Omeros 4.64 1.89 68.73% -69.05%
Pfizer 52.31 -0.12 -0.23% 31.66%
Roche Holding 320.40 1.85 0.58% -8.34%
Sanofi 97.52 1.18 1.22% 10.94%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
Teva Pharmaceutical Industries Ltd 2,670.00 -83.00 -3.01% -18.10%
UCB 82.60 1.96 2.43% -8.22%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

ChemoCentryx
ChemoCentryx, Inc. is a biopharmaceutical company that focuses on the development and commercialization of medications targeting inflammatory disorders, autoimmune diseases and cancer. Its drug candidates are designed to selectively block a specific chemoattractant receptor, leaving the rest of the immune system intact. The Company's lead drug candidate Avacopan is a potential first-in-class, an orally-administered molecule that targeted mode of action in the treatment of antineutrophil cytoplasmic antibodies (ANCA) vasculitis and other complement-driven autoimmune and inflammatory diseases. The Company is also developing Avacopan for the treatment of severe (Hurley stage III) hidradenitis suppurativa (HS). Its CCX559 is an orally administered inhibitor for programmed death protein one/programmed death-ligand 1 (PD-1/PD-L1), which are developing for the treatment of various cancers.